By Michael McCaughan
The health care reform legislation enacted in 2010 expanded eligibility for the 340B discount while lowering prices under the program....
Refining 340B: A Big Year Ahead
The health care reform legislation enacted in 2010 expanded eligibility for the 340B discount while lowering prices under the program. Manufacturers were able to fend off expansion of the discount to the inpatient setting, but failed to get the program itself eliminated as expanded insurance phases in. In 2011, there is plenty of activity in Washington that will affect the growth of the 340B program and the impact of the discounts on pharma.
More from Market Access
• By
Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.
• By
Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
• By
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
• By
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
More from Pink Sheet
• By
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
• By
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
• By
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.